These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 30978501)
1. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung. Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501 [TBL] [Abstract][Full Text] [Related]
2. Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria. Driver BR; Portier BP; Mody DR; Deavers M; Bernicker EH; Kim MP; Teh BS; Santacruz JF; Kopas L; Munden RF; Cagle PT Arch Pathol Lab Med; 2016 Apr; 140(4):312-7. PubMed ID: 26430808 [TBL] [Abstract][Full Text] [Related]
3. Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China. Zhao Y; Dong Y; Zhao R; Zhang B; Wang S; Zhang L; Hu M; He Q; Zhang W; Han B Clin Lung Cancer; 2020 Sep; 21(5):e355-e362. PubMed ID: 32139332 [TBL] [Abstract][Full Text] [Related]
4. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532 [TBL] [Abstract][Full Text] [Related]
5. [Clinicopathologic features and genetic profile of the redefined large cell lung carcinoma]. Hou LK; Zhang LP; Zhang W; Huang Y; Wu W; Dong ZW; Wu CY Zhonghua Bing Li Xue Za Zhi; 2017 May; 46(5):298-302. PubMed ID: 28468033 [No Abstract] [Full Text] [Related]
6. Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. Rekhtman N; Tafe LJ; Chaft JE; Wang L; Arcila ME; Colanta A; Moreira AL; Zakowski MF; Travis WD; Sima CS; Kris MG; Ladanyi M Mod Pathol; 2013 Apr; 26(4):511-22. PubMed ID: 23196793 [TBL] [Abstract][Full Text] [Related]
7. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512 [TBL] [Abstract][Full Text] [Related]
8. Pulmonary large cell carcinoma lacking squamous differentiation is clinicopathologically indistinguishable from solid-subtype adenocarcinoma. Hwang DH; Szeto DP; Perry AS; Bruce JL; Sholl LM Arch Pathol Lab Med; 2014 May; 138(5):626-35. PubMed ID: 23738762 [TBL] [Abstract][Full Text] [Related]
9. Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging. Kratz JR; Haro GJ; Cook NR; He J; Van Den Eeden SK; Woodard GA; Gubens MA; Jahan TM; Jones KD; Kim IJ; He B; Jablons DM; Mann MJ J Thorac Oncol; 2019 Jul; 14(7):1223-1232. PubMed ID: 30959120 [TBL] [Abstract][Full Text] [Related]
10. Molecular dissection of large cell carcinomas of the lung with null immunophenotype. Harms A; Endris V; Winter H; Kriegsmann M; Stenzinger A; Schirmacher P; Warth A; Kazdal D Pathology; 2018 Aug; 50(5):530-535. PubMed ID: 29958730 [TBL] [Abstract][Full Text] [Related]
11. Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France. Guibert N; Barlesi F; Descourt R; Léna H; Besse B; Beau-Faller M; Mosser J; Pichon E; Merlio JP; Ouafik L; Guichard F; Mastroianni B; Moreau L; Wdowik A; Sabourin JC; Lemoine A; Missy P; Langlais A; Moro-Sibilot D; Mazières J J Thorac Oncol; 2017 Jun; 12(6):963-973. PubMed ID: 28189832 [TBL] [Abstract][Full Text] [Related]
12. Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology. Rossi G; Mengoli MC; Cavazza A; Nicoli D; Barbareschi M; Cantaloni C; Papotti M; Tironi A; Graziano P; Paci M; Stefani A; Migaldi M; Sartori G; Pelosi G Virchows Arch; 2014 Jan; 464(1):61-8. PubMed ID: 24221342 [TBL] [Abstract][Full Text] [Related]
13. The introduction of systematic genomic testing for patients with non-small-cell lung cancer. Cardarella S; Ortiz TM; Joshi VA; Butaney M; Jackman DM; Kwiatkowski DJ; Yeap BY; Jänne PA; Lindeman NI; Johnson BE J Thorac Oncol; 2012 Dec; 7(12):1767-1774. PubMed ID: 23154547 [TBL] [Abstract][Full Text] [Related]
14. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250 [TBL] [Abstract][Full Text] [Related]
15. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients. Fathi Z; Mousavi SAJ; Roudi R; Ghazi F PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458 [TBL] [Abstract][Full Text] [Related]
17. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042 [TBL] [Abstract][Full Text] [Related]
18. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Rekhtman N; Paik PK; Arcila ME; Tafe LJ; Oxnard GR; Moreira AL; Travis WD; Zakowski MF; Kris MG; Ladanyi M Clin Cancer Res; 2012 Feb; 18(4):1167-76. PubMed ID: 22228640 [TBL] [Abstract][Full Text] [Related]
19. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations. Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840 [TBL] [Abstract][Full Text] [Related]
20. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases. Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]